ARK Space & Defense or SPDR Aerospace & Defense: Which ETF Can Power Your Portfolio?

The article favors SPDR S&P Aerospace & Defense ETF (XAR) over ARK Space & Defense Innovation ETF (ARKX), citing XAR's 0.35% expense ratio versus 0.75%, lower beta of 1.03 versus 1.42, and shallower four-year maximum drawdown of 21.0% versus 25.5%. ARKX led on trailing one-year returns, 15.1% versus 1.8%, and three-year annualized returns, 30.4% versus 28.8%, but XAR outperformed over five years at 16.5% annualized versus 9.0%. Both funds were negative year-to-date, with XAR down 11% and ARKX down nearly 13%, while XAR offers broader equal-weighted exposure across 50 U.S. aerospace and defense holdings.

Analysis

This is not a standalone catalyst for either ETF; the actionable implication is factor exposure. XAR is effectively a small/mid-cap aerospace-and-defense allocation with recurring rebalancing into laggards, whereas ARKX carries materially more manager, liquidity, and single-name-duration risk. In a sustained procurement upcycle, smaller subsystem, maintenance, autonomy, and counter-drone vendors can outgrow primes because incremental program awards move the revenue needle faster; AVAV, KTOS, VSEC, and MOG.A are more relevant beneficiaries than mega-cap RTX or LHX.

The data quality warrants caution: the purported SpaceX public ticker and portfolio composition must be independently verified before using ARKX as a space-industry proxy. If the fund's economic exposure is concentrated in private-company-linked or high-multiple technology holdings, its return will be driven more by equity-duration and capital-markets conditions than defense appropriations. That makes ARKX vulnerable to a real-rate backup even if defense budgets remain supportive.

Over the next 1-3 months, a broad risk-off move or delays in federal appropriations would likely hurt XAR's smaller holdings disproportionately despite their defense end-market exposure. Over 6-18 months, the key differentiator is whether production bottlenecks ease: firms with aftermarket/service revenue and scarce-component content should defend margins better than pure platform manufacturers. The contrarian view is that the apparent lower-risk profile of XAR may not persist in a small-cap liquidity drawdown; its diversification reduces idiosyncratic risk but does not eliminate cyclicality in lower-tier suppliers.

Key Decisions for Investors

• No directional trade solely on this comparison; treat it as an ETF-flow and positioning item rather than a fundamental catalyst. Verify ARKX holdings, concentration, and private-company valuation methodology before establishing exposure.
• For a 6-12 month defense-upcycle expression, prefer a modest long XAR versus short ITA pair: XAR should outperform if awards broaden beyond primes into smaller suppliers. Target 8-12% relative upside; exit if appropriations are delayed beyond the next funding deadline or if XAR underperforms ITA by 5% after a confirmed budget resolution.
• Use AVAV and KTOS as higher-beta watch-list longs only after evidence of booked orders/backlog conversion at earnings; size smaller than prime-contractor exposure given valuation and program-timing risk. Falsify on guidance cuts, adverse procurement decisions, or a 10%+ reduction in funded counter-UAS/autonomy programs.
• Avoid using ARKX as a clean space proxy until underlying holdings are validated. If confirmed to have meaningful high-duration technology exposure, hedge any ARKX position with IWM or QQQ puts during periods of rising real yields rather than assuming defense demand provides downside protection.